LACTOFIN 15ML | Suppression of lactation in dogs and cats

LACTOFIN

50 mcg/ml oral solution, for dogs and cats.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance:
Cabergoline…………………………………..………50 µg
Excipient, csp. ………………………………..………….1ml
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Oral solution.
4. CLINICAL DATA
4.1 Target species
Dogs and cats.
4.2 Indications for use, specifying the target species
Treatment of pseudopregnancy in bitches.
Suppression of lactation in bitches and cats.
As an adjuvant in the treatment of eclampsia and mastitis accompanied by discharge
dairy in bitches and cats.
4.3 Contraindications
None.
4.4 Special warnings for each target species
As additional supportive measures, during treatment the
intake of water and carbohydrates, as well as increasing the exercise of the animals
treaties.
4.5 Special precautions for use
Special precautions for use in animals
Cabergoline can cause abortions in bitches in the final phase of pregnancy and in

Cabergoline may cause transient hypotension in treated animals and its use
concomitant with other hypotensive drugs or in animals under the influence of
anesthetic agents after surgical procedures can lead to hypotension
significant. In these cases, cabergoline is contraindicated..
Special precautions to be taken by the person administering the medicinal product
to the animals
Administer the drug with caution.
It is convenient to wash your hands after use.
Avoid contact with skin and eyes. In case of accidental contact with the skin, it must be
be washed immediately with soap and water.
People with a known hypersensitivity to cabergoline should avoid all contact
with the veterinary drug.
The drug should be handled with care by pregnant women or women in
childbearing age who are taking contraceptives. Disposable gloves are recommended
when handling the medication.
In case of accidental ingestion, consult a doctor immediately and show him the
leaflet or label.
4.6 Adverse reactions (frequency and seriousness)
Occasionally there have been some cases of vomiting taking place
generally within one to two hours after the first dose is administered. He
treatment should not be interrupted, as this phenomenon does not usually occur in
subsequent treatments.
During treatment a slight loss of appetite may occur.
4.7 Use during pregnancy, lactation or lay
The indication of the veterinary medicinal product excludes its use during pregnancy.
Inhibition of prolactin release causes rapid cessation of secretion
of milk and the consequent reduction in the volume of the breast.
Do not use in lactating bitches or cats unless discontinuation of dosing is necessary.
lactation.
4.8 Interaction with other medicinal products and other forms of interaction
None known.
4.9 Amounts to be administered and administration route
Lactofin can be administered orally directly into the animal's mouth or mixed
with the feed
Bitches: 0,1 ml/kg body weight (equivalent to 5 µg/kg body weight) once
once a day for 4-6 days, depending on the severity of the condition
clinical.

3/5
In case of recurrence, the treatment can be repeated according to the forms of
administration described above.
The drug should be used under the direct supervision of a veterinarian.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
In case of overdose, the first symptom to appear is vomiting. Saying
effect can be antagonized by parenteral administration of an agent
antidopaminergic such as metoclopramide
The emetic effect is dose-dependent. It has been observed in dogs treated with doses of
10 µg/kg and above. The dose that causes emesis in 50% of the treated animals
(ED50) is 19 µg/kg. In cats, the dose with emetic effects is 15 µg/kg.
4.11 Wait times
Not applicable.
5 PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Other gynecological drugs. Prolactin inhibitors.
ATCvet code: QG02CB03.

See technical sheet

LACTOFIN